Cocrystal Pharma To Develop Additional Two Antiviral Drug Candidates For COVID-19

Cocrystal Pharma Inc COCP has selected two investigational novel antiviral drug candidates for further development as oral treatments for COVID-19. 

  • CDI-988 and CDI-873 target a highly conserved region in the active site of SARS-CoV-2 main (3CL) protease required for viral RNA replication. 
  • Cocrystal plans to initiate a first-in-human trial with one selected candidate as soon as possible this year.
  • Although CDI-988 and CDI-873 are chemically differentiatedboth exhibited superior in vitro potency against SARS-CoV-2 with activity maintained against current variants of concern, including omicron. 
  • Related: Cocrystal's COVID-19 Antiviral Candidate Shows Potency Against Omicron Variant.
  • Both candidates demonstrated a favorable safety profile and pharmacokinetic properties in preclinical studies supportive of daily oral dosing.
  • "In addition to initiating two COVID-19 trials in 2022, we anticipate completion of our influenza CC-42344 Phase 1 study this year," said James Martin, Cocrystal's CFO and interim co-CEO.
  • Cocrystal received guidance from the FDA for further development of CDI-45205 in response to the Company's pre-Investigational New Drug (IND) briefing package. 
  • Price Action: COCP shares are up 0.56% at $0.51 during the market session on the last check Thursday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsPenny StocksHealth CareGeneralBriefsCOVID-19 Coronavirus
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!